Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
Condition(s) studied
Investigational drug(s) / intervention(s)
Tozorakimab: Single IV dose of tozorakimab on Day 1.
Placebo: Single IV dose of matching placebo on Day 1.
Study summary
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
Eligibility
Primary outcome measure(s)
- Proportion of participants who die or progress to Invasive Mechanical Ventilation (IMV) / Extracorporeal Membrane Oxygen (ECMO) — by Day 28
To evaluate the effect of tozorakimab versus placebo as an add on to Standard of Care (SoC) in participants with viral lung infection requiring supplemental oxygen on the prevention of death or progression to IMV/ECMO.
Trial sites (471)
| Facility | City | Region | Status |
|---|---|---|---|
| Research Site | Birmingham | Alabama | Not Yet Recruiting |
| Research Site | Mobile | Alabama | Recruiting |
| Research Site | Phoenix | Arizona | Completed |
| Research Site | Phoenix | Arizona | Withdrawn |
| Research Site | Tucson | Arizona | Recruiting |
| Research Site | Chula Vista | California | Withdrawn |
| Research Site | Fresno | California | Recruiting |
| Research Site | La Mesa | California | Withdrawn |
| Research Site | Los Angeles | California | Withdrawn |
| Research Site | Newport Beach | California | Recruiting |
| Research Site | Torrance | California | Recruiting |
| Research Site | Colorado Springs | Colorado | Recruiting |
| Research Site | Denver | Colorado | Withdrawn |
| Research Site | Washington D.C. | District of Columbia | Recruiting |
| Research Site | Bradenton | Florida | Completed |
| Research Site | Bradenton | Florida | Withdrawn |
| Research Site | Gainesville | Florida | Recruiting |
| Research Site | Jacksonville | Florida | Recruiting |
| Research Site | Lakeland | Florida | Recruiting |
| Research Site | Miami | Florida | Withdrawn |
| Research Site | South Pasadena | Florida | Completed |
| Research Site | St. Petersburg | Florida | Withdrawn |
| Research Site | Tampa | Florida | Recruiting |
| Research Site | Atlanta | Georgia | Withdrawn |
| Research Site | Boise | Idaho | Recruiting |
| Research Site | Chicago | Illinois | Completed |
| Research Site | Elmhurst | Illinois | Withdrawn |
| Research Site | Evanston | Illinois | Recruiting |
| Research Site | Fort Wayne | Indiana | Withdrawn |
| Research Site | Iowa City | Iowa | Withdrawn |
| Research Site | Kansas City | Kansas | Withdrawn |
| Research Site | Louisville | Kentucky | Recruiting |
| Research Site | Baton Rouge | Louisiana | Recruiting |
| Research Site | New Orleans | Louisiana | Withdrawn |
| Research Site | Shreveport | Louisiana | Completed |
| Research Site | Annapolis | Maryland | Recruiting |
| Research Site | Silver Spring | Maryland | Completed |
| Research Site | Springfield | Massachusetts | Completed |
| Research Site | Worcester | Massachusetts | Completed |
| Research Site | Detroit | Michigan | Recruiting |
+ 431 more sites — see the full list on the official registry below.
More AstraZeneca trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05624450 on ClinicalTrials.gov ↗ ← All trials in Italy